scholarly journals The importance of validating intracranial bleeding diagnoses in The Health Improvement Network, United Kingdom: Misclassification of onset and its impact on the risk associated with low‐dose aspirin therapy

2018 ◽  
Vol 28 (2) ◽  
pp. 134-139 ◽  
Author(s):  
Lucía Cea Soriano ◽  
David Gaist ◽  
Montse Soriano‐Gabarró ◽  
Luis A. García Rodríguez
Keyword(s):  
United Kingdom ◽  
Low Dose ◽  
Aspirin Therapy ◽  
Intracranial Bleeding ◽  
Health Improvement ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
The Health Improvement Network

scholarly journals Incidence of intracranial bleeds in new users of low-dose aspirin: a cohort study using The Health Improvement Network

2017 ◽  
Vol 15 (6) ◽  
pp. 1055-1064 ◽  
Author(s):  
L. Cea Soriano ◽  
D. Gaist ◽  
M. Soriano-Gabarró ◽  
L. A. García Rodríguez
Keyword(s):  
Cohort Study ◽  
Low Dose ◽  
Health Improvement ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
The Health Improvement Network

Long-term adherence to low-dose aspirin therapy for cardiovascular prevention in routine clinical practice in United Kingdom and Germany

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P Vora ◽  
M Soriano-Gabarro ◽  
B Russel ◽  
H Morgan Stewart
Keyword(s):  
United Kingdom ◽  
Index Date ◽  
Low Dose ◽  
Aspirin Therapy ◽  
Funding Source ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Cvd Prevention

Abstract Background Low-dose aspirin is effective in the prevention of ischemic vascular events and studies have shown a preventative effect on colorectal cancer (CRC). However, adherence to therapy is likely an important factor for these benefits to be seen and non-adherence is associated with sub-optimal outcomes. Purpose To assess the long-term adherence to low-dose aspirin therapy in the primary and secondary cardiovascular (CVD) prevention population Methods This retrospective cohort study used data from United Kingdom (UK) – The Health Improvement Network Database and Germany (DE) – IQVIA Disease Analyzer and analyzed using an adaptation of Observational Health Data Sciences and Informatics (OHDSI) ATLAS Tool. Patients 18 years or older, with at least two prescriptions of low-dose aspirin (75–100mg) within the first year of index date during the study period between 2007 and 2018, and with at least 12 months of observation before and after the index date were included in the study. The patients with a CVD diagnosis or a CABG/PCI procedure before the index date or a prescription of dual antiplatelet at index date were classified as secondary CVD prevention. The remaining patients were classified as potential primary CVD prevention. The index date was first prescription of low-dose aspirin. Adherence was calculated using medication possession ratio (MPR) which is number of days of medication supplied within the refill interval divided by number of days in the refill interval. Long term adherence was divided in three categories namely patients with ≤2 years, 2-≤5 years, and 5-≤10 years of follow-up. Results The total number of patients receiving low-dose aspirin was 327,806 (183,089 in UK and 144,717 in DE with up to 10 years of follow-up). A total of 112,887 and 101,704 received low-dose aspirin for secondary CVD prevention; 70,202 and 43,013 potentially for primary CVD prevention in UK and DE, respectively. Median adherence to low-dose aspirin in UK and DE for patients with ≤2 years of follow-up was 88% and 80% for secondary CVD prevention, respectively; 84% and 74% for 2-≤5 years; and 75% and 59% for 5-≤10 years, respectively. Median adherence to low-dose aspirin in UK and DE for patients with ≤2 years was 76% and 75% for potential primary CVD prevention; 65% and 66% for 2-≤5 years; 49% and 49% for 5-≤10 years, respectively (Figure). Conclusion The long-term adherence to low dose aspirin was quite high with more than half the patients being adherent to their treatment. Overall, the adherence was higher in secondary compared to primary CVD prevention. The estimates for adherence might be underestimated due to potential over the counter use of low-dose aspirin. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Bayer AG

scholarly journals Chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation in middle-aged humans

2009 ◽  
Vol 106 (2) ◽  
pp. 500-505 ◽  
Author(s):  
Lacy A. Holowatz ◽  
W. Larry Kenney
Keyword(s):  
Low Dose ◽  
Aspirin Therapy ◽  
Oral Temperature ◽  
Middle Aged ◽  
Doppler Flowmetry ◽  
Healthy Humans ◽  
Cutaneous Vasodilation ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Reflex Cutaneous Vasodilation

Full expression of reflex cutaneous vasodilation is dependent on cyclooxygenase- (COX) and nitric oxide synthase- (NOS) dependent mechanisms. Low-dose aspirin therapy is widely prescribed to inhibit COX-1 in platelets for atherothrombotic prevention. We hypothesized that chronic COX inhibition with daily low-dose aspirin therapy (81 mg) would attenuate reflex vasodilation in healthy human skin. Two microdialysis fibers were placed in forearm skin of seven middle-aged (57 ± 3 yr), normotensive, healthy humans with no preexisting cardiovascular disease, taking daily low-dose aspirin therapy (aspirin: 81 mg), and seven unmedicated, healthy, age-matched control (no aspirin, 55 ± 3 yr) subjects, with one site serving as a control (Ringer) and the other NOS inhibited (NOS inhibited: 10 mM NG-nitro-l-arginine methyl ester). Red cell flux was measured over each site by laser-Doppler flowmetry, as reflex vasodilation was induced by increasing core temperature (oral temperature) 1.0°C using a water-perfused suit. Cutaneous vascular conductance (CVC) was calculated (CVC = flux/mean arterial pressure) and normalized to maximal CVC (CVCmax; 28 mM sodium nitroprusside). CVCmax was not affected by either aspirin or NOS inhibition. The plateau in cutaneous vasodilation during heating (change in oral temperature = 1.0°C) was significantly attenuated in the aspirin group (aspirin: 25 ± 3% CVCmax vs. no aspirin: 50 ± 7% CVCmax, P < 0.001 between groups). NOS inhibition significantly attenuated %CVCmax in both groups (aspirin: 17 ± 2% CVCmax, no aspirin: 23 ± 3% CVCmax; P < 0.001 vs. control), but this attenuation was less in the no-aspirin treatment group ( P < 0.001). This is the first observation that chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation through both COX- and NOS-dependent mechanisms.

The safety of continued low dose aspirin therapy during Complete Supine Percutaneous Nephrolithotomy (csPCNL)

2021 ◽  
Author(s):  
S. Falahatkar ◽  
S. Esmaeili ◽  
N. Rastjou Herfeh ◽  
E. Kazemnezhad ◽  
R. Falahatkar ◽  
...  
Keyword(s):  
Percutaneous Nephrolithotomy ◽  
Low Dose ◽  
Aspirin Therapy ◽  
Dose Aspirin ◽  
Low Dose Aspirin

Minor Oral Surgery Without Stopping Daily Low-Dose Aspirin Therapy: A Study of 51 Patients

2005 ◽  
Vol 63 (9) ◽  
pp. 1262-1265 ◽  
Author(s):  
Gautam A. Madan ◽  
Sonal G. Madan ◽  
Gauri Madan ◽  
A.D. Madan
Keyword(s):  
Low Dose ◽  
Oral Surgery ◽  
Aspirin Therapy ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Minor Oral Surgery
Sign in / Sign up

Export Citation Format

Share Document